Protagonist Therapeutics, Inc - 10-Q Filing

Protagonist Therapeutics reports third quarter 2026 financial results and updates on Takeda and Janssen collaboration agreements.

SEC EDGAR ·

Tickers: $PTGX

Read the full article at SEC EDGAR

More Regulatory news